Targeting BTK through microRNA in chronic lymphocytic leukemia

Arianna Bottoni, Lara Rizzotto, Tzung Huei Lai, Chaomei Liu, Lisa L. Smith, Rose Mantel, Sean Reiff, Dalia El-Gamal, Karilyn Larkin, Amy J. Johnson, Rosa Lapalombella, Amy Lehman, William Plunkett, John C. Byrd, James S. Blachly, Jennifer A. Woyach, Deepa Sampath

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Bruton's tyrosine kinase (BTK) is a critical mediator of survival in B-cell neoplasms. Although BTK inhibitors have transformed therapy in chronic lymphocytic leukemia (CLL), patients with high-risk genetics are at risk for relapse and have a poor prognosis. Identification of novel therapeutic strategies for this group of patients is an urgent unmet clinical need, and therapies that target BTK via alternative mechanisms may fill this niche. Herein, we identify a set of microRNAs (miRs) that target BTK in primary CLL cells and show that the histone deacetylase (HDAC) repressor complex is recruited to these miR promoters to silence their expression. Targeting the HDACs by using either RNA interference against HDAC1 in CLL or a small molecule inhibitor (HDACi) in CLL and mantle cell lymphoma restored the expression of the BTK-targeting miRs with loss of BTK protein and downstream signaling and consequent cell death. We have also made the novel and clinically relevant discovery that inhibition of HDAC induces the BTK-targeting miRs in ibrutinib-sensitive and resistant CLL to effectively reduce both wild-type and C481S-mutant BTK. This finding identifies a novel strategy that may be promising as a therapeutic modality to eliminate the C481S-mutant BTK clone that drives resistance to ibrutinib and provides the rationale for a combination strategy that includes ibrutinib to dually target BTK to suppress its prosurvival signaling.

Original languageEnglish (US)
Pages (from-to)3101-3112
Number of pages12
JournalBlood
Volume128
Issue number26
DOIs
StatePublished - Dec 29 2016

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
MicroRNAs
Histone Deacetylases
Agammaglobulinaemia tyrosine kinase
Mantle-Cell Lymphoma
Cell death
Therapeutics
RNA Interference
B-Lymphocytes
Cell Death
Clone Cells
Cells
RNA
Recurrence
Molecules
Survival

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Bottoni, A., Rizzotto, L., Lai, T. H., Liu, C., Smith, L. L., Mantel, R., ... Sampath, D. (2016). Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood, 128(26), 3101-3112. https://doi.org/10.1182/blood-2016-07-727750

Targeting BTK through microRNA in chronic lymphocytic leukemia. / Bottoni, Arianna; Rizzotto, Lara; Lai, Tzung Huei; Liu, Chaomei; Smith, Lisa L.; Mantel, Rose; Reiff, Sean; El-Gamal, Dalia; Larkin, Karilyn; Johnson, Amy J.; Lapalombella, Rosa; Lehman, Amy; Plunkett, William; Byrd, John C.; Blachly, James S.; Woyach, Jennifer A.; Sampath, Deepa.

In: Blood, Vol. 128, No. 26, 29.12.2016, p. 3101-3112.

Research output: Contribution to journalArticle

Bottoni, A, Rizzotto, L, Lai, TH, Liu, C, Smith, LL, Mantel, R, Reiff, S, El-Gamal, D, Larkin, K, Johnson, AJ, Lapalombella, R, Lehman, A, Plunkett, W, Byrd, JC, Blachly, JS, Woyach, JA & Sampath, D 2016, 'Targeting BTK through microRNA in chronic lymphocytic leukemia', Blood, vol. 128, no. 26, pp. 3101-3112. https://doi.org/10.1182/blood-2016-07-727750
Bottoni A, Rizzotto L, Lai TH, Liu C, Smith LL, Mantel R et al. Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood. 2016 Dec 29;128(26):3101-3112. https://doi.org/10.1182/blood-2016-07-727750
Bottoni, Arianna ; Rizzotto, Lara ; Lai, Tzung Huei ; Liu, Chaomei ; Smith, Lisa L. ; Mantel, Rose ; Reiff, Sean ; El-Gamal, Dalia ; Larkin, Karilyn ; Johnson, Amy J. ; Lapalombella, Rosa ; Lehman, Amy ; Plunkett, William ; Byrd, John C. ; Blachly, James S. ; Woyach, Jennifer A. ; Sampath, Deepa. / Targeting BTK through microRNA in chronic lymphocytic leukemia. In: Blood. 2016 ; Vol. 128, No. 26. pp. 3101-3112.
@article{334307a053964451ae8fb0781c44a628,
title = "Targeting BTK through microRNA in chronic lymphocytic leukemia",
abstract = "Bruton's tyrosine kinase (BTK) is a critical mediator of survival in B-cell neoplasms. Although BTK inhibitors have transformed therapy in chronic lymphocytic leukemia (CLL), patients with high-risk genetics are at risk for relapse and have a poor prognosis. Identification of novel therapeutic strategies for this group of patients is an urgent unmet clinical need, and therapies that target BTK via alternative mechanisms may fill this niche. Herein, we identify a set of microRNAs (miRs) that target BTK in primary CLL cells and show that the histone deacetylase (HDAC) repressor complex is recruited to these miR promoters to silence their expression. Targeting the HDACs by using either RNA interference against HDAC1 in CLL or a small molecule inhibitor (HDACi) in CLL and mantle cell lymphoma restored the expression of the BTK-targeting miRs with loss of BTK protein and downstream signaling and consequent cell death. We have also made the novel and clinically relevant discovery that inhibition of HDAC induces the BTK-targeting miRs in ibrutinib-sensitive and resistant CLL to effectively reduce both wild-type and C481S-mutant BTK. This finding identifies a novel strategy that may be promising as a therapeutic modality to eliminate the C481S-mutant BTK clone that drives resistance to ibrutinib and provides the rationale for a combination strategy that includes ibrutinib to dually target BTK to suppress its prosurvival signaling.",
author = "Arianna Bottoni and Lara Rizzotto and Lai, {Tzung Huei} and Chaomei Liu and Smith, {Lisa L.} and Rose Mantel and Sean Reiff and Dalia El-Gamal and Karilyn Larkin and Johnson, {Amy J.} and Rosa Lapalombella and Amy Lehman and William Plunkett and Byrd, {John C.} and Blachly, {James S.} and Woyach, {Jennifer A.} and Deepa Sampath",
year = "2016",
month = "12",
day = "29",
doi = "10.1182/blood-2016-07-727750",
language = "English (US)",
volume = "128",
pages = "3101--3112",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "26",

}

TY - JOUR

T1 - Targeting BTK through microRNA in chronic lymphocytic leukemia

AU - Bottoni, Arianna

AU - Rizzotto, Lara

AU - Lai, Tzung Huei

AU - Liu, Chaomei

AU - Smith, Lisa L.

AU - Mantel, Rose

AU - Reiff, Sean

AU - El-Gamal, Dalia

AU - Larkin, Karilyn

AU - Johnson, Amy J.

AU - Lapalombella, Rosa

AU - Lehman, Amy

AU - Plunkett, William

AU - Byrd, John C.

AU - Blachly, James S.

AU - Woyach, Jennifer A.

AU - Sampath, Deepa

PY - 2016/12/29

Y1 - 2016/12/29

N2 - Bruton's tyrosine kinase (BTK) is a critical mediator of survival in B-cell neoplasms. Although BTK inhibitors have transformed therapy in chronic lymphocytic leukemia (CLL), patients with high-risk genetics are at risk for relapse and have a poor prognosis. Identification of novel therapeutic strategies for this group of patients is an urgent unmet clinical need, and therapies that target BTK via alternative mechanisms may fill this niche. Herein, we identify a set of microRNAs (miRs) that target BTK in primary CLL cells and show that the histone deacetylase (HDAC) repressor complex is recruited to these miR promoters to silence their expression. Targeting the HDACs by using either RNA interference against HDAC1 in CLL or a small molecule inhibitor (HDACi) in CLL and mantle cell lymphoma restored the expression of the BTK-targeting miRs with loss of BTK protein and downstream signaling and consequent cell death. We have also made the novel and clinically relevant discovery that inhibition of HDAC induces the BTK-targeting miRs in ibrutinib-sensitive and resistant CLL to effectively reduce both wild-type and C481S-mutant BTK. This finding identifies a novel strategy that may be promising as a therapeutic modality to eliminate the C481S-mutant BTK clone that drives resistance to ibrutinib and provides the rationale for a combination strategy that includes ibrutinib to dually target BTK to suppress its prosurvival signaling.

AB - Bruton's tyrosine kinase (BTK) is a critical mediator of survival in B-cell neoplasms. Although BTK inhibitors have transformed therapy in chronic lymphocytic leukemia (CLL), patients with high-risk genetics are at risk for relapse and have a poor prognosis. Identification of novel therapeutic strategies for this group of patients is an urgent unmet clinical need, and therapies that target BTK via alternative mechanisms may fill this niche. Herein, we identify a set of microRNAs (miRs) that target BTK in primary CLL cells and show that the histone deacetylase (HDAC) repressor complex is recruited to these miR promoters to silence their expression. Targeting the HDACs by using either RNA interference against HDAC1 in CLL or a small molecule inhibitor (HDACi) in CLL and mantle cell lymphoma restored the expression of the BTK-targeting miRs with loss of BTK protein and downstream signaling and consequent cell death. We have also made the novel and clinically relevant discovery that inhibition of HDAC induces the BTK-targeting miRs in ibrutinib-sensitive and resistant CLL to effectively reduce both wild-type and C481S-mutant BTK. This finding identifies a novel strategy that may be promising as a therapeutic modality to eliminate the C481S-mutant BTK clone that drives resistance to ibrutinib and provides the rationale for a combination strategy that includes ibrutinib to dually target BTK to suppress its prosurvival signaling.

UR - http://www.scopus.com/inward/record.url?scp=85015010926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015010926&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-07-727750

DO - 10.1182/blood-2016-07-727750

M3 - Article

C2 - 27756747

AN - SCOPUS:85015010926

VL - 128

SP - 3101

EP - 3112

JO - Blood

JF - Blood

SN - 0006-4971

IS - 26

ER -